A new study led by University of Cincinnati Cancer Center researchers details how the accumulation of copper helps clear cell renal cell carcinoma (ccRCC)—the most common kidney cancer—grow and advance in stage. The findings ...
Nov 7, 2024
0
9
A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, the most common form ...
Oct 3, 2024
0
26
A study led by researchers at UT Southwestern Medical Center reveals significant disparities across the country in the use of immunotherapy for patients with advanced kidney and bladder cancers. The findings, published in ...
Sep 4, 2024
1
0
Belzutifan, a hypoxia-inducible factor 2α (HIF-2α) inhibitor, improves progression-free survival and objective responses over everolimus among patients with advanced clear-cell renal cell carcinoma, according to a study ...
Aug 23, 2024
0
0
Most tumors release various signaling molecules to support their incessant growth, invasion, and metastasis. Some of these molecules, known as tumor angiogenic factors (TAF), are able to stimulate the formation of new blood ...
Aug 9, 2024
0
0
Eligibility requirements for clinical trials help protect patients whose comorbidities may put them at an additional risk of severe harm from the treatment being tested. Further, they help ensure that analyses are performed ...
Jun 27, 2024
0
0
For nearly two decades, how kidney cancer becomes resistant to rapalog drugs has baffled the scientific community. Now a study by researchers at UT Southwestern Medical Center's Kidney Cancer Program sheds light. Published ...
Jun 12, 2024
0
15
Advanced clear cell renal cell carcinoma (ccRCC) is a deadly form of kidney cancer with few treatment options; even with new immunotherapies, only around one in 10 patients ultimately survive.
Jun 4, 2024
0
0
The number of mutations in the DNA of cancerous tumors may not be an indicator of how well patients will respond to immune checkpoint inhibitors (ICIs), a commonly prescribed type of immunotherapy, a team led by UT Southwestern ...
May 23, 2024
0
37
Patients with very advanced solid tumors saw no significant improvement in overall survival after receiving systemic therapy, according to a study published in JAMA Oncology by researchers at The University of Texas MD Anderson ...
May 16, 2024
0
14
Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule, the very small tubes in the kidney that filter the blood and remove waste products. RCC is the most common type of kidney cancer in adults, responsible for approximately 80% of cases. It is also known to be the most lethal of all the genitourinary tumors.[citation needed] Initial treatment is most commonly a radical or partial nephrectomy and remains the mainstay of curative treatment. Where the tumor is confined to the renal parenchyma, the 5-year survival rate is 60-70%, but this is lowered considerably where metastases have spread. It is relatively resistant to radiation therapy and chemotherapy, although some cases respond to immunotherapy. Targeted cancer therapies such as sunitinib, temsirolimus, bevacizumab, interferon-alpha, and sorafenib have improved the outlook for RCC (progression-free survival), although they have not yet demonstrated improved survival.
This text uses material from Wikipedia licensed under CC BY-SA
